This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.
This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
FOR MORE INFORMATION
Contact us at
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for STARGARDT DISEASE
OCUGEN PROTOCOL NUMBER
NUMBER OF SUBJECTS
Up to 42 adults who meet eligibility criteria
Male & Female
August 2023 – December 2025